Authorized purpose: Automate labeling, visualization, and volumetric quantification of segmentable brain structures from MR images for trained medical-imaging professionals.
Clinical role
Segmentation, labeling, volumetric quantification, and report visualization.
Images and patients
MRI · Brain, including segmentable cortical/subcortical structures, vessels, and WMH/lesion regions.
Key limitation
Keep in mind: Results should be reviewed by a trained physician; the packet describes quality-control checks, outlier removal, and user review of inappropriate/hidden regions. No clinical test was required for substantial equivalence, so the packet does not establish diagnostic outcome performance.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Automate labeling, visualization, and volumetric quantification of segmentable brain structures from MR images for trained medical-imaging professionals.
Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Brain, including segmentable cortical/subcortical structures, vessels, and WMH/lesion regions. Input: 3D T1-weighted brain MR images and 2D T2 FLAIR brain MR images; the comparison table specifies 1.5T and 3T input.
Who uses it?Intended users: Trained healthcare professionals who work with medical imaging.
What does the software produce?Output: Automatic segmentation/labeling of 104 brain structures including two vessels, WMH and lesion quantification from T2 FLAIR, volumetric measurements, color-map visualization, normative-percentile/prior comparison when applicable, and downloadable/printable reports.
What is its most important limitation?Key limitation: Results should be reviewed by a trained physician; the packet describes quality-control checks, outlier removal, and user review of inappropriate/hidden regions. No clinical test was required for substantial equivalence, so the packet does not establish diagnostic outcome performance.
Clinical takeaway. Clinical role: Automate labeling, visualization, and volumetric quantification of segmentable brain structures from MR images for trained medical-imaging professionals.
Evidence takeaway. Evidence from the reviewed source record: FDA K231398 reports nonclinical verification/validation plus segmentation-accuracy and test-retest reproducibility testing; no clinical test was required. Segmentation used Dice Similarity Coefficient with acceptance criteria of 0.80 for brain and WMH regions, and reproducibility used ICC criteria of 0.965 for brain structures and 0.988 for WMH; reported results exceeded criteria. The packet gives no test-set sample size.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Automate labeling, visualization, and volumetric quantification of segmentable brain structures from MR images for trained medical-imaging professionals.
Automatic segmentation/labeling of 104 brain structures including two vessels, WMH and lesion quantification from T2 FLAIR, volumetric measurements, color-map visualization, normative-percentile/prior comparison when applicable, and downloadable/printable reports.
Results should be reviewed by a trained physician; the packet describes quality-control checks, outlier removal, and user review of inappropriate/hidden regions. No clinical test was required for substantial equivalence, so the packet does not establish diagnostic outcome performance.
FDA K231398 reports nonclinical verification/validation plus segmentation-accuracy and test-retest reproducibility testing; no clinical test was required. Segmentation used Dice Similarity Coefficient with acceptance criteria of 0.80 for brain and WMH regions, and reproducibility used ICC criteria of 0.965 for brain structures and 0.988 for WMH; reported results exceeded criteria. The packet gives no test-set sample size.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA K231398 reports nonclinical verification/validation plus segmentation-accuracy and test-retest reproducibility testing; no clinical test was required. Segmentation used Dice Similarity Coefficient with acceptance criteria of 0.80 for brain and WMH regions, and reproducibility used ICC criteria of 0.965 for brain structures and 0.988 for WMH; reported results exceeded criteria. The packet gives no test-set sample size.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
VUNO Med-DeepBrain regulatory performance study summary
DesignStand-Alone Performance
PopulationAdult
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K231398
IndependenceIndependence not established
K231398
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K231398. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: 3D T1-weighted brain MR images and 2D T2 FLAIR brain MR images; the comparison table specifies 1.5T and 3T input.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: Data can be received from and sent to PACS using DICOM; the comparison table describes a cloud-based software package installed on user hardware.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes VUNO Med-DeepBrain deployment as cloud based, stating that it is a cloud-based software package installed on the user's hardware. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "The deployment characteristics are the same. Both are cloud-based software package that is installed on the user’s hardware." … "The product is used in an office-like environment. environment. Deployment Cloud based Cloud based". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Automatic segmentation/labeling of 104 brain structures including two vessels, WMH and lesion quantification from T2 FLAIR, volumetric measurements, color-map visualization, normative-percentile/prior comparison when applicable, and downloadable/printable reports.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Automatic segmentation/labeling of 104 brain structures including two vessels, WMH and lesion quantification from T2 FLAIR, volumetric measurements, color-map visualization, normative-percentile/prior comparison when applicable, and downloadable/printable reports.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes VUNO Med-DeepBrain deployment as cloud based, stating that it is a cloud-based software package installed on the user's hardware. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "The deployment characteristics are the same. Both are cloud-based software package that is installed on the user’s hardware." … "The product is used in an office-like environment. environment. Deployment Cloud based Cloud based". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
ACR AI Central provides an exact-submission model card for VUNO Med-DeepBrain; FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
23Fields reviewed
9Source classes checked
1Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate record. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission
No public price or quote for the exact K231398 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-08 - Exact FDA submission
Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-08 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: ANDI 2.2 processes brain MR images for atlas-assisted visualization, segmentation and volumetric quantification, presenting adjunctive DICOM-readable information for trained medical professionals; it does not predict, diagnose or interpret brain health.
Authorized purpose: Neurophet AQUA is intended for automatic labeling, visualization, and volumetric quantification of segmentable brain structures and lesions from a set of MR images; volumetric data may be compared to reference percentile data.
Authorized purpose: Morph automatically labels, visualizes, and volumetrically quantifies segmentable brain structures from MR images and may compare measurements with reference percentile data; it is adjunctive and not the sole basis for final decisions.
Authorized purpose: Post-process previously acquired cervical-spine MR images to segment vertebrae and disks, calculate quantitative measurements, label out-of-range values, and export results for user review and interpretation.
Modality
MRI
Anatomy
Cervical spine: vertebrae C3-C7 and disks C2C3 through C7T1
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.